EA201591433A1 - Офтальмологические составы - Google Patents

Офтальмологические составы

Info

Publication number
EA201591433A1
EA201591433A1 EA201591433A EA201591433A EA201591433A1 EA 201591433 A1 EA201591433 A1 EA 201591433A1 EA 201591433 A EA201591433 A EA 201591433A EA 201591433 A EA201591433 A EA 201591433A EA 201591433 A1 EA201591433 A1 EA 201591433A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ophthalmic
compound
producing
ophthalmic compositions
relates
Prior art date
Application number
EA201591433A
Other languages
English (en)
Inventor
Уилльям К. Маквикар
Харун Такрури
Original Assignee
Инотек Фармасьютикалс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инотек Фармасьютикалс Корпорейшн filed Critical Инотек Фармасьютикалс Корпорейшн
Publication of EA201591433A1 publication Critical patent/EA201591433A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к офтальмологическому составу, который содержит тонкодисперсную частицу соединения А в водной суспензии, и способу его получения. Более конкретно, изобретение относится к офтальмологической водной суспензии для местного применения, которую можно получить путем суспендирования тонкодисперсных частиц соединения А в водной среде, содержащей поверхностно-активное вещество и борную кислоту. В изобретении также предложены способы получения офтальмологических составов и способы их применения.
EA201591433A 2013-03-15 2014-03-14 Офтальмологические составы EA201591433A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793273P 2013-03-15 2013-03-15
PCT/US2014/027662 WO2014152723A1 (en) 2013-03-15 2014-03-14 Ophthalmic formulations

Publications (1)

Publication Number Publication Date
EA201591433A1 true EA201591433A1 (ru) 2015-12-30

Family

ID=51528080

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591433A EA201591433A1 (ru) 2013-03-15 2014-03-14 Офтальмологические составы

Country Status (16)

Country Link
US (3) US9522160B2 (ru)
EP (1) EP2968389A4 (ru)
JP (1) JP2016513706A (ru)
KR (1) KR20150139501A (ru)
CN (1) CN105188714A (ru)
AU (1) AU2014239222A1 (ru)
BR (1) BR112015021870A2 (ru)
CA (1) CA2903114A1 (ru)
CL (1) CL2015002721A1 (ru)
EA (1) EA201591433A1 (ru)
HK (1) HK1214951A1 (ru)
MX (1) MX2015013234A (ru)
NZ (1) NZ630759A (ru)
PH (1) PH12015502003A1 (ru)
SG (1) SG11201506882YA (ru)
WO (1) WO2014152723A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119969A1 (en) * 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
MX2017007318A (es) * 2014-12-03 2017-08-25 Inotek Pharmaceuticals Corp Metodos de prevencion, reduccion o tratamiento de degeneracion macular.
US10945598B2 (en) * 2019-02-06 2021-03-16 Jichi Medical University Method for assisting corneal severity identification using unsupervised machine learning
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935635B1 (ru) 1970-12-28 1974-09-25
CH563405A5 (ru) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
DE2226295A1 (de) 1972-05-30 1973-12-20 Henning Berlin Gmbh Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
DE2342479A1 (de) 1973-08-23 1975-03-13 Merck Patent Gmbh Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
GB2001976B (en) 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
US4849311A (en) 1986-09-24 1989-07-18 Toa Nenryo Kogyo Kabushiki Kaisha Immobilized electrolyte membrane
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
ES2317964T5 (es) 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP3020580B2 (ja) 1990-09-28 2000-03-15 株式会社日立製作所 マイクロ波プラズマ処理装置
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
HU212570B (en) 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
DK62692D0 (ru) 1992-05-14 1992-05-14 Novo Nordisk As
WO1994002497A1 (en) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5338430A (en) 1992-12-23 1994-08-16 Minnesota Mining And Manufacturing Company Nanostructured electrode membranes
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
DE69428536T2 (de) 1993-07-13 2002-06-06 Nasa A3 -adenosin -rezeptor agonisten
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
EP0704215A3 (en) 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CN1164122A (zh) 1996-03-01 1997-11-05 株式会社日立制作所 等离子处理机及其处理方法
WO1997033590A1 (en) 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2289731A1 (en) 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6358536B1 (en) 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2775901B1 (fr) 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CA2337499A1 (en) 1998-07-16 2000-01-27 The Trustees Of The University Of Pennsylvania Methods for reducing intraocular pressure using a3-adenosine antagonists
BR9914526A (pt) 1998-10-16 2001-07-03 Pfizer Derivados de adenina
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
CN1166677C (zh) 1999-06-22 2004-09-15 Cv治疗公司 噻吩a2a受体激动剂
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
GB9930071D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
CN1450896A (zh) 2000-07-28 2003-10-22 印斯拜尔药品股份有限公司 用吲哚衍生物降低眼内压的方法
ATE292973T1 (de) 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
EP1423175B1 (en) 2001-08-08 2013-10-02 Brown University Research Foundation Methods for micronization of hydrophobic drugs
CA2460911C (en) 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
JP2005530736A (ja) 2002-04-18 2005-10-13 シーブイ・セラピューティクス・インコーポレイテッド ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法
AU2003221762B2 (en) 2002-04-30 2008-09-25 Alcon, Inc. Agents which regulate, inhibit or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20060034941A1 (en) 2002-12-23 2006-02-16 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
US8008338B2 (en) * 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
CA2554716A1 (en) 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
MXPA06013560A (es) 2004-05-26 2007-03-15 Inotek Pharmaceuticals Corp Derivados de purina como agonistas del receptor de adenosina a1 y metodos de uso de los mismos.
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
US7271157B2 (en) 2004-07-12 2007-09-18 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
JP5203214B2 (ja) 2005-11-30 2013-06-05 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
ES2385924T3 (es) 2006-02-02 2012-08-03 Allergan, Inc. Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
BRPI0709124A2 (pt) 2006-03-23 2011-06-28 Inotek Pharmaceuticals Corp composto purina e métodos de uso dos mesmos
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
CA2658646A1 (en) 2006-07-25 2008-01-31 Osmotica Corp. Ophthalmic solutions
AU2007307157A1 (en) 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
SI2083629T2 (sl) * 2006-11-10 2015-03-31 Basf Se Kristalna modifikacija fipronila
JP5576659B2 (ja) 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ Ｔｒｋレセプター調節因子の使用方法
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
US20100272711A1 (en) 2007-12-12 2010-10-28 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
CA2714516A1 (en) 2008-02-07 2009-08-13 Gilead Palo Alto, Inc. Abca-1 elevating compounds and the use thereof
CN102215869B (zh) 2008-11-13 2015-05-13 通用医疗公司 用于通过调整bmp-6来调节铁稳态的方法和组合物
PL2424546T3 (pl) 2009-05-01 2016-04-29 Inotek Pharmaceuticals Corp Sposób obniżania ciśnienia wewnątrzgałkowego u ludzi
KR101690816B1 (ko) * 2009-06-25 2016-12-28 라이온 가부시키가이샤 안과용 조성물 및 백탁·침전 억제 방법
BR112012009841A2 (pt) * 2009-10-26 2016-11-29 Inotek Pharmaceuticals Corp formulação oftálmica e processo para a sua preparação
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
EP2523669B1 (en) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
ES2613254T3 (es) 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular
RS55616B1 (sr) 2010-03-19 2017-06-30 Inotek Pharmaceuticals Corp Kombinovane kompozicije adenozinskih a1 agonista i ne-selektivnih beta-adrenergičnih receptor blokera za snižavanje intraokularnog pritiska
US8501708B2 (en) 2010-03-26 2013-08-06 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
WO2011119969A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
US9278991B2 (en) * 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
BR112015022044A2 (pt) 2013-03-15 2017-07-18 Inotek Pharmaceuticals Corp um método de proporcionar neutroproteção ocular

Also Published As

Publication number Publication date
CA2903114A1 (en) 2014-09-25
US20140271876A1 (en) 2014-09-18
KR20150139501A (ko) 2015-12-11
US20170049799A1 (en) 2017-02-23
EP2968389A4 (en) 2016-08-24
JP2016513706A (ja) 2016-05-16
MX2015013234A (es) 2016-04-15
SG11201506882YA (en) 2015-09-29
EP2968389A1 (en) 2016-01-20
CN105188714A (zh) 2015-12-23
BR112015021870A2 (pt) 2017-07-18
US9522160B2 (en) 2016-12-20
HK1214951A1 (zh) 2016-08-12
AU2014239222A1 (en) 2015-10-01
US20170151273A1 (en) 2017-06-01
WO2014152723A1 (en) 2014-09-25
PH12015502003A1 (en) 2016-01-11
CL2015002721A1 (es) 2016-09-30
NZ630759A (en) 2017-07-28

Similar Documents

Publication Publication Date Title
UA114289C2 (uk) Неводні концентровані суспензійні композиції зі зниженою в'язкістю на основі антитіл
EA201591433A1 (ru) Офтальмологические составы
CL2017000969A1 (es) Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014)
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
WO2014194117A3 (en) Novel metalloproteases
EA201690930A1 (ru) Композиции и способы модуляции фарнезоидных х-рецепторов
EA201400869A1 (ru) Масляная дисперсия, способ её получения, упаковка и применение борной кислоты в качестве стимулятора консервации масляной дисперсии
MX2016003660A (es) Conjugados de partícula similar a virus para el diagnóstico y tratamiento de tumores.
EA201590887A1 (ru) Композиция
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
TR201908247T4 (tr) Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri.
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
EA201591826A1 (ru) Тонкодисперсные сухие композиции ретиноидного активного средства и содержащие их составы для местного применения
UA112331C2 (uk) Композиція, що містить блок-співконденсати пропіл-функціоналізованих силіконатів і силікатів лужних металів, а також спосіб їх одержання
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c
BR112015028824A2 (pt) composição de tensoativo concentrada
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201590673A1 (ru) Слоистые двойные гидроксиды
IN2015DN00085A (ru)
EA201400282A1 (ru) Сокристаллы ципродинила и дитианона